
Receiving NADT for 6 Months Doesn’t Impact Outcomes in Intermediate-Risk Prostate Cancer After EBRT
Despite clinical trial findings, real-world evidence shows adding 6 months of neoadjuvant deprivation therapy (NADT) to external-beam radiation therapy (EBRT) for patients with intermediate-risk prostate cancer did not improve prostate cancer–specific …